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• Patients with two or more chronic conditions and taking multiple prescription medications are 
eligible to receive medication therapy management (MTM) services as part of  their Medicare Part 
D or individual prescription coverage.
• MTM is a service or group of  services designed to optimize therapeutic outcomes for patients.1
Typically, these services are provided face-to-face or telephonically, however, direct patient 
outreach is not always feasible
• MTM is underutilized given that only about 11% of  eligible Medicare beneficiaries accept these 
services. 2
• Interprofessional communication is essential for providing comprehensive, quality healthcare for 
patients.3
• Innovative, interprofessional programs integrating pharmacists and primary care providers (PCPs) 
are needed to facilitate MTM service provision for patients who cannot directly participate.4
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Capitalizing on Opportunities for Reaching Patients: Utilization of  Providers In Delivering 
Medication Therapy Management (MTM) Services
BACKGROUND
PROGRAM DESCRIPTION
• Patients met these POP eligibility criteria: (1) receiving 
multiple medications from a particular PCP (identified from 
the claims history); and (2) not reachable or unable to directly 
participate in a pharmacy staff-provided telephone MTM 
consultation.
• Prescription drug claims were provided by the patient’s health 
plan and uploaded into the RxCompanion© software. 
• The prescriber most often providing care or prescriptions for a 
patient receiving multiple medications was designated as the 
PCP.
• PCP offices were contacted via facsimile to establish a line of  
communication for CMR completion for eligible patients. 
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• Goal: To determine if  PCP outreach (e.g., via facsimile and telephone) was an efficient method 
for completing telephonic comprehensive medication reviews (CMRs) for patients who were 
eligible to receive MTM services but were unable to directly participate (e.g., cognitive 
impairment) in the MTM process.
² SinfoníaRx, in collaboration with the University of  Arizona Medication Management Center 
(UAMMC) and The Ohio State University Medication Management Program (OSUMMP), 
developed the Provider Outreach Program (POP) to address this deficiency (e.g., CMR 
completion) in patient care. 
• Purpose: The intent of  the POP was to maximize patient outcomes by engaging PCPs via a 
collaborative, interprofessional healthcare process to:
² Deliver personalized pharmacist-delivered CMRs via telephone; 
² Resolve pharmacotherapy-related medication problems; and
² Obtain patient-specific information needed (e.g., active medications) from providers to 
facilitate the CMR on the patient’s behalf. 
GOAL AND PURPOSE
RESULTS
DISCUSSION
• The POP can be utilized as a method to strengthen the outcomes of  the standard process to 
increase the number of  patients who benefit from MTM services. 
• Future investigation is warranted to: (1) determine the significance of  PCP’s refusal to participate 
in the POP and to identify reasons for nonparticipation; (2) evaluate differences in provider-
pharmacists communication channels by state; and (3) expand the POP to include more PCPs to 
serve a multitude of  patients. 
• Additional work is needed to determine whether other provider outreach programs produce 
similar results when implemented with diverse populations and other settings. 
Table 1 presents the number of  
medication lists successfully 
received following PCP contact 
through POP.
• Designated PCPs in 21 states 
participated in the POP and 
received facsimiles requesting 
patient-related medication 
lists-placement.
• Of  the total 52,170 faxes 
sent, 9,043 medication lists 
were received (17.3%) from 
PCPs.
CONCLUSIONS
• The POP established communication with designated PCPs to facilitate CMR completion to 
improve patient outcomes. 
• Interprofessional collaboration and coordination with PCPs through the POP was an effective 
method for providing comprehensive medication-related care to patients.  
• Facsimile and telephonic communication methods improved interprofessional collaboration 
between pharmacists and PCPs.
• Patients who are unreachable via traditional MTM program communication channels may 
benefit from a Provider Outreach Program.
Limitations:
² The lower CMR completion rate of  the standard MTM process may have been due to the 
timeframe of  the study and lower patient availability. 
² POP’s faxing capabilities (e.g., manual) may have been inadequate for contacting PCPs.
² Medication lists provided by PCPs after POP completion were excluded from the analysis.
Patient Identification
• Facsimiles were generated and sent to identified PCPs containing:
² A brief  program description and purpose of  the 
communication
² A list of  patients under the PCP’s care
• The facsimiles requested patient information including:
² Up-to-date medication list
² Allergies
² Cognitive impairment status
• PCPs were asked to provide a preferred date, time, and telephone 
number for subsequent contact by a pharmacy technician. 
• Pharmacy technicians and registered nurses established initial 
communication with PCPs prior to triaging the call to the 
pharmacist.
• A pharmacist completed the medication reconciliation and 
documentation of  allergies and cognitive impairment status for 
each patient.
• Discrepancies between the medication list provided by the 
designated PCP and the medication list loaded into the 
RxCompanion© software, were noted and addressed immediately.
• Pharmacist-led interventions, utilizing evidence-based medicine 
targeted pharmacotherapy-related medication problems.
• Collaboration between the designated PCP and the pharmacist 
enhanced the MTM process by incorporating recommendations 
into the individualized therapeutic patient plan.
Table 2 compares the number of  
CMRs completed by the call center 
(standard MTM) versus the POP.
• There was a 3.8-fold difference 
in successful CMR completion 
rates between the POP (16.4%) 
and the standard MTM 
program (4.3%).
POP Nonparticipation
Provider Outreach CMR Completion
CMR Completion
POP Success Story
• During a medication review with the PCP, the pharmacist determined that 
a patient was receiving JANUVIA (sitagliptin) 100mg daily and 
METFORMIN 500mg twice daily from one provider as well as 
JANUMET (sitagliptin/metformin) 50mg/500mg twice daily from a 
different provider.  
• JANUVIA and METFORMIN taken with JANUMET is considered a 
therapeutic duplication; the claims data revealed concurrent therapy for 
approximately 2 years.
• The PCP agreed to follow up with the other prescriber, pharmacy and 
patient to resolve the duplication in therapy.
Table 3 outlines some reasons why PCPs failed to respond to communication initiated via facsimile 
contact.
• For the PCP practices, the most common reason for nonparticipation was lack of  a fax number 
for the respective office.
• In addition to practice-related issues, patients opted out or disenrolled from MTM services were 
another reason for PCP nonparticipation.
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Table	2:	Comprehensive	Medication	Review	(CMR)	
Completion	Rates	for	Standard	MTM	versus	Provider	
Outreach	Program	(POP)
Total	
Outbound	
Calls
Standard	MTM
CMR	
Completion	
N	(%)
Total	
Facsimiles	
Sent	to	
Providers
POP	CMR	
Completi
on	
N	(%)
2,494,030 107,435	(4.3) 52,170 8,532	
(16.4)
Table	3: Reasons	for	Nonparticipation	in	the	Provider	Outreach	
Program	(N=3,443)*
Reasons	for	Nonparticipation Total	N	(%)
PCP Practice-related	Reasons
No	facsimile number	provided	nor	obtained	 2,682	(77.9)
Incorrect facsimile	information 448	(13.0)
Provider unwilling	to	participate 111	(3.2)
Release of	information	or	payment	requested	by	PCP 59	(1.7)
Proof	of	contract	requested	by	PCP 16	(0.5)
Patient-related	Reasons
Patient	opted	out	or	disenrolled	from	Medicare	Coverage	 127	(3.7)
*Value	does	not	represent	total	number	of	facsimiles	that	went	unanswered	by	PCPs
Table	1: Response	Rates	for	Medication	Lists	Obtained	
Following	Provider	Outreach	for		Participating	States
Participating State Faxes	SentN	(%)
Medication List	
Received	
N	(%)
Texas 1,372	(2.6) 283	(20.6)
California 2,824	(5.4) 483	(17.1)
Washington 537	(1.0) 112 (20.9)
Maine 116	(0.2) 37	(31.9)
Wisconsin 2,272	(4.4) 485	(21.3)
New	Hampshire 913	(1.8) 298	(32.6)
New	York 20,972	(40.2) 2,203	(10.5)
Michigan 2,222	(4.3) 318	(14.3)
Massachusetts 913	(1.8) 397	(43.5)
Tennessee 4,912	(9.4) 1,526	(31.1)
Ohio 8,289	(15.9) 1,882	(22.7)
Indiana 1,520	(2.9) 304	(20.0)
Connecticut 1,072	(2.1) 206	(19.2)
Montana 378	(0.7) 63	(16.7)
Virginia 295	(0.6) 44	(14.9)
Kentucky 393	(0.8) 55	(14.0)
Nevada 1,799	(3.4) 245	(13.6)
Colorado 223	(0.4) 28	(12.6)
Hawaii 110	(0.2) 9	(8.1)
West	Virginia 227	(0.4) 20	(8.8)
New	Jersey 811	(1.6) 45	(5.5)
Total 52,170 9,043	(17.3)
